THE CLAIMS

What is claimed is:

1. A solid pharmaceutical composition comprising norastemizole, or a pharmaceutically acceptable salt thereof; a diluent; a binder; a disintegrant; and a lubricant; wherein the diluent, binder, disintegrant, and lubricant are not the same.

2. The solid pharmaceutical composition of claim 1, wherein the composition is free of lactose.

3. The pharmaceutical composition of claim 1, wherein the disintegrant is present in an amount of from about 0.5 to 15 percent by weight of the pharmaceutical composition, and the lubricant is present in an amount of up to about 1 percent by weight of the pharmaceutical composition.

4. The solid pharmaceutical composition of claim 1 in a tablet or capsule dosage form.

5. The solid pharmaceutical composition of claim 1, wherein the norastemizole, or a pharmaceutically acceptable salt thereof, is present in an amount of from about 1 mg to 200 mg.

6. The solid pharmaceutical composition of claim 1, wherein the norastemizole, or a pharmaceutically acceptable salt thereof, is present in an amount of from about 2 mg to 100 mg.

7. The solid pharmaceutical composition of claim 1, further comprising pseudoephedrine, or a pharmaceutically acceptable salt thereof.

8. The solid pharmaceutical composition of claim 7, wherein the pseudoephedrine, or a pharmaceutically acceptable salt thereof, is adapted for sustained release.

9. A solid pharmaceutical composition comprising norastemizole, or a pharmaceutically acceptable salt thereof; microcrystalline cellulose; pregelatanized starch; croscarmellose sodium; and magnesium stearate.

10. The solid pharmaceutical composition of claim 9, wherein the norastemizole, or a pharmaceutically acceptable salt thereof, is present in an amount of from about 1 to 50 percent; the microcrystalline cellulose is present in an amount of from about 20 to 90 percent; the pregelatanized starch is present in an amount of from about 5 to 75 percent; the croscarmellose sodium is present in an amount of from about 1 to 5 percent; and the magnesium stearate is present in an amount of from about 0.05 to 0.8 percent by weight of the pharmaceutical composition.

11. The solid pharmaceutical composition of claim 9 in a tablet or capsule dosage form.

12. The solid pharmaceutical composition of claim 9, wherein the norastemizole, or a pharmaceutically acceptable salt thereof, is present in an amount of from about 1 mg to 200 mg.

13. The solid pharmaceutical composition of claim 12, wherein the norastemizole, or a pharmaceutically acceptable

salt thereof, is present in an amount of from about 2 mg to 100 mg.

14. The solid pharmaceutical composition of claim 9, further comprising pseudoephedrine, or a pharmaceutically acceptable salt thereof.

15. The solid pharmaceutical composition of claim 14, wherein the pseudoephedrine, or a pharmaceutically acceptable salt thereof, is adapted for sustained release.

16. A solid pharmaceutical composition comprising (i) a therapeutically effective amount of coated particles of norastemizole, or a pharmaceutically acceptable salt thereof, wherein said particles are coated with an inert coating and (ii) a pharmaceutically acceptable excipient.

17. The solid pharmaceutical composition of claim 16, wherein the coated particles of norastemizole, or a pharmaceutically acceptable salt thereof, comprise granulated norastemizole particles, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

18. The solid pharmaceutical composition of claim 16, wherein the inert coating comprises an inert film-forming agent in a solvent.

19. The solid pharmaceutical composition of claim 18, wherein the inert film-forming agent is methylcellulose, hydroxymethyl cellulose, carboxymethyl cellulose, hydroxypropylmethylcellulose, hydroxypropyl cellulose, hydroxyethylcellulose, methylhydroxyethylcelluose, sodium carboxymethylcellulose, or a mixture thereof.

20. The solid pharmaceutical composition of claim 18, wherein the inert film-forming agent is cross-linked ethylcellulose.

21. The solid pharmaceutical composition of claim 16 adapted as a quick dissolving dosage form.

22. A solid pharmaceutical composition comprising norastemizole, or a pharmaceutically acceptable salt thereof; a diluent; a binder; a disintegrant; and a lubricant; wherein the disintegrant is a super disintegrant.

23. The solid pharmaceutical composition of claim 22, wherein the super disintegrant is croscarmellose sodium or sodium starch glycolate.

24. The solid pharmaceutical composition of claim 23, wherein the super disintegrant is croscarmellose sodium.

25. A method of treating an allergic disorder in a mammal comprising administering to a mammal in need of treatment a therapeutically effective amount of the composition of claim 1.

26. The method of claim 25, wherein said mammal is a human.

27. The method of claim 25, wherein said allergic disorder is allergic rhinitis.

28. The method of claim 25, wherein said allergic disorder is solar uticaria or symptomatic dermographism.

29. A method of treating an allergic disorder in a mammal comprising administering to a mammal in need of treatment a therapeutically effective amount of the composition of claim 9.

30. The method of claim 29, wherein said mammal is a human.

31. The method of claim 29, wherein said allergic disorder is allergic rhinitis.

32. The method of claim 29, wherein said allergic disorder is solar uticaria or symptomatic dermographism

33. A method of treating an allergic disorder in a mammal comprising administering to a mammal in need of treatment a therapeutically effective amount of the composition of claim 16.

34. The method of claim 33, wherein said mammal is a human.

35. The method of claim 33, wherein said allergic disorder is allergic rhinitis.

36. The method of claim 33, wherein said allergic disorder is solar uticaria or symptomatic dermographism

37. A method of treating an allergic disorder in a mammal comprising administering to a mammal in need of treatment a therapeutically effective amount of the composition of claim 22.

38. The method of claim 37, wherein said mammal is a human.

39. The method of claim 37, wherein said allergic disorder is allergic rhinitis.

40. The method of claim 37, wherein said allergic disorder is solar uticaria, symptomatic dermographism.